Infectious Diseases

Audrey Schuetz, M.D., provides a detailed overview of Mayo Clinic Laboratories’ new culture-based extended spectrum beta lactamase (ESBL) testing. Used to screen for the presence of multi-drug resistant gram-negative bacteria in donor stool intended for fecal microbiota transplantation, the screening test is performed on stool or swab samples taken from around the anus to detect potentially harmful ESBL bacteria that could jeopardize the outcomes of fecal microbiota transplants -- especially in patients who carry the bacteria in their gut without getting sick.

Joseph Yao, M.D., explains how Mayo Clinic Laboratories’ SARS four-target test for viral respiratory disease can enhance patient care. The test detects RNA from SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus, or RSV. RSV — which poses significant risks for infants and patients with underlying health conditions — can be treated if diagnosed early.

If you need a test for COVID-19, a variety of options are now available. But how do you know which one is right for you? Use this guide from Mayo Clinic Laboratories to sort through the choices and help you decide.

This week on the podcast, Brad Karon, M.D., Ph.D., chair of Mayo Clinic’s Division of Clinical Core Laboratory Services, joins "Answers From the Lab" with Bobbi Pritt, M.D. and William Morice II, M.D., Ph.D. This episode focuses on at-home testing for COVID-19, including the types of tests that are available, when they should be used, and how well they work.

Audrey Schuetz, M.D., discusses Mayo Clinic Laboratories' PCR assay that identifies two recently described staphylococcus species. The assay is unique in its ability to distinguish the new organisms from Staphylococcus aureus, providing clearer results that ultimately improve patient care.

This "Pathways" program provides a Clinical Pathology case that includes a history, potential answers, rationale, and relevant references. This case sub-specialty is Clinical Microbiology.

Nancy Wengenack, Ph.D., director of the Mycology and Microbacteriology Laboratories in Mayo Clinic’s Department of Laboratory Medicine and Pathology, joins the "Answers From the Lab" podcast this week. In this episode, Dr. Wengenack and Bobbi Pritt, M.D., discuss the fungal infection Candida auris.

It’s been understood for some time that an infection of B. mayonii, a rare species of bacterium, results in high levels of spirochetes in the peripheral blood. But actually being able to visualize them on a routine peripheral blood smear may allow for improved recognition of this uncommon cause of Lyme disease.

Matthew Binnicker, Ph.D., director of the Clinical Virology Laboratory in Mayo Clinic’s Division of Clinical Microbiology, considers the prospects for COVID-19 this fall as the traditional influenza season ramps up.

Bobbi Pritt, M.D., discusses how Mayo Clinic Labs’ updated PCR assay for West Nile virus provides increased sensitivity to detect virus RNA in multiple sources, identifies two virus lineages, and confirms diagnosis.

When most of the world was still struggling to understand how COVID-19 would affect their lives, Atria Senior Living took steps to protect their vulnerable residents and staff.

Mayo Clinic Laboratories now offers a noninvasive approach for the molecular detection of H. pylori, with results that include prediction of clarithromycin resistance delivered within 24 hours.